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Abstract
P. aeruginosa 1244 pilin is covalently modified with a
carbohydrate moiety, which is structurally similar to the
lipopolysaccharide (LPS) O-antigen repeating unit. Studies were
conducted using transmission electron microscopy and scanning
electron microscopy with the monoclonal glycan-specific
antibody, 11.14, to determine the location of the glycan.

It

was found that the glycan is evenly distributed over the entire
surface of the pilin fiber and not restricted to the tip.
immunogenicity of the pilin glycan was also studied.

The

Rabbits

were immunized with pure LPS-free pili to determine if the pili
produce anti-LPS antibodies.

The serum obtained from the

rabbits was analyzed using ELISA assay and was found to have a
high titer of IgG anti-LPS antibodies.

Mice were also immunized

with pure reaggregated pili to determine a titer level to IgG,
IgA, and IgM antibodies.

A response was seen with the IgM

antibodies in the serum, however the levels were similar to the
sham-immunized mice.

Protection studies were also conducted

using the rabbit serum to determine if there was serum
resistance or PMN killing.

There was no serum sensitivity or

PMN killing detected in the strains tested.
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I.
A.

Introduction
General characteristics of Pseudomonas aeruginosa
Pseudomonas aeruginosa, a member of the family

Pseudomonadacae (Stanislavsky, 1997), is a rod-shaped Gramnegative bacterium.

It is considered an aerobic opportunistic

pathogen (Odeh, 2000). P. aeruginosa was first isolated by
Gessard in 1882 and named Bacillus pyocyaneus (Lyczak et al,
2000).
P. aeruginosa is ubiquitous to the environment due to
several factors. The first factor is its ability to utilize many
environmental compounds as energy sources which allows it to
colonize in areas with limited resources. Secondly, it has the
ability to colonize multiple environmental niches due to its
large genome size and genetic complexity (Stover et al, 2000).
P. aeruginosa is relatively easy to identify in the
laboratory.

The bacterium grows on many types of media such as

LB (Luria Bertani), CAYE, and TSA.

Its unique characteristic in

the laboratory is the production of pyocyanin, a water-soluble
green phenazine pigment which causes a green color to the
culture medium (Odeh, 2000).
B.

Medical Aspects of P. aeruginosa
Since P. aeruginosa is an opportunistic pathogen, it

frequently causes infections in immunocompromised individuals.
P. aeruginosa was ranked the second most frequent pathogen in
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surgery and third in medicine.

P. aeruginosa is among the most

frequently isolated organisms from pus, sputum, blood, and other
clinical material of patients with Gram-negative hospital
infections (Stanislavsky and Lam, 1997). It’s ability to adapt
to many types of environments with sparse nutrients makes it a
dangerous pathogen.
P. aeruginosa is a common cause of infection among burn
victims.

These patients have very little skin over their

wounds, therefore, eliminating the protective barrier against P.
aeruginosa.

A burn wound with a P. aeruginosa infection is

characterized by a blue-green color, caused by the pigment
pyocyanin released in subcutaneous fat tissue (Pruitt et al.,
1998).

Pseudomonas aeruginosa may appear in the patients’ stool

initially from ingested foods and then autoinoculate the burn
wounds located on the body (Bodey et al., 1983).

Currently, an

infected burn wound is being treated with an application of
citric acid which seems to eliminate an infection of P.
aeruginosa quicker and stimulates the formation of granulation
tissue which is commonly seen within freshly healing tissue
(Nagoba et al., 1998).

This new aggressive treatment varies

from the normal protocol which is betadine, 0.5% silver nitrate,
or silver sulfadiazine creams (Bodey et al., 1983).
P. aeruginosa is also a common cause of corneal infections
in humans.

The bacterium will usually only be found isolated in
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contact-lens wearers with keratitis because the ability to
adhere to healthy corneal epithelial cells is extremely low
(Lomholt et al., 2001).

Small scratches on the cornea caused by

improper use of contact lenses give P. aeruginosa opportunity to
infect the wounded area.

The source of bacteria is usually the

contact lens storage cases, commercial solutions, and various
household surfaces (Micallef et al., 2000).

Corneal infections

with P. aeruginosa can also begin by aerosol exposure from
mechanical ventilation that some patients need as part of their
course of treatment (Smulders et al., 1999).

Mechanical

ventilation treatment can also cause pneumonia.

P. aeruginosa

can also colonize the cornea in areas of tissue damage which
expose various receptors for adhesion (Hazlet et al, 1986).
Common adhesins for corneal infection of P. aeruginosa are
pilin, alginate, and the ADP-ribosylating toxin exoenzyme S
which gives the bacterium an advantage over other bacteria
species (Fleizig et al., 1996).

Recently described by Evans et

al., (2002) lipopolysaccharide (LPS) plays a major part in
causing infection of the cornea.

LPS has an interactive role

with the internalization survival by protection against
bacterial killing (Evans et al., 2002).
P. aeruginosa is generally associated with cystic fibrosis,
the most common lethal autosomal recessive disorder among
caucasians.

It is a genetic disease which causes the body to
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produce an abnormally thick, sticky mucus due to a mutation in
the chloride channel protein called cystic fibrosis
transmembrane conductance regulator (CFTR).

The core

polysaccharide of LPS attaches the bacteria to CFTR.
aeruginosa bound in this manner can then invade them.

P.
The thick

mucous prevents the bacteria from being expelled which leads to
life-threatening lung infections.

As the result from abnormal

salt and water regulation, the thick mucus accumulates in the
intestines and lungs, therefore, causing malnutrition, frequent
respiratory problems, difficulty breathing, and lung damage.
One of every 3900 live births of all Americans have cystic
fibrosis.

The average life span of these babies is

approximately 33 years.

These individuals are taught to wash

their hands often to avoid all types of infections including P.
aeruginosa.

It is probably the most prevalent bacterium found

in cystic fibrosis patients causing death in over 90% of
individuals with CF (Darling and Evans, 2003).

Most patients

are infected with the non-mucoidal strains of P. aeruginosa,
however as the infection progresses, the bacterium transitions
to the mucoidal strain.

This leads to a poor prognosis because

at this point, P. aeruginosa can colonize the mucosal membrane
and cause chronic lung infections.

A murine model of chronic

mucosal colonization by P. aeruginosa was developed to evaluate
the prevention of the initial bacterial colonization (Pier,
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1992).

In the future, this model may provide evidence for an

effective therapeutic solution.

Maintenance chemotherapy is

currently the only prolongment for CF patients.

With this

treatment, ninety percent of the patients now have the ability
to survive at least ten more years after the onset of a chronic
infection (Hoiby, 1995).
Research is still being done on new treatments for P.
aeruginosa infections in the lungs of cystic fibrosis patients.
Nitric oxide (NO) production is being closely examined to
determine the effects on P. aeruginosa in the lungs of both
normal and diseased.

The third isoform of NO synthase (NOS),

inducible NOS (iNOS), is expressed after an inflammatory
stimulus in the lungs of normal individuals and produces NO that
generates antimicrobial activity against a number of bacteria,
fungi, protozoans, and helminthes (Fang, 1997).

It was found

that cystic fibrosis patients have a lack of epithelial iNOS
located in their lungs (Kelley et al., 1998).

The study looked

at whether P. aeruginosa is affected by NO production from iNOS.
The investigators found that NO production did reduce the amount
of P. aeruginosa that adhered to human bronchial epithelial
cells and enhanced killing of internalized bacteria (Darling and
Evans, 2003) This would lead us to think that the lack of
epithelial iNOS in cystic fibrosis patients does contribute to
P. aeruginosa infections and colonization.
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Future aims for this

study is to create an aerosol agent that would increase the
amount of iNOS in the lungs of cystic fibrosis patients.
P. aeruginosa can infect many different parts of the body.
The skin when it is abnormal and unhealthy is a part of the body
that P. aeruginosa is able to colonize.

When the skin is wet

constantly, burned, or lacerated, P. aeruginosa will usually
begin to colonize the weakened area. Other possible infection
areas are corneal ulcers in the eyes, otitis externa in the
ears, nose, throat, Pseudomonas meningitis of the brain and
spinal cord, endocarditis in the heart, enteritis in the
gastrointestinal tract, urinary tract infections, ostermyelitis
in bones and joints, and septicemia of the blood.

Most

individuals who become infected by P. aeruginosa are
immunocompromised.

Since these patients’ primary host defenses

such as complement and PMN’s (poly-morpho-nuclear leukocytes)
are weakened by cancer or disease, they cannot fight off the
bacterial infection like healthy individuals would be able to do
(Bodey et al., 1983).
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C.

Virulence Factors
P. aeruginosa is such an effective pathogen due to the

number of virulence factors it possesses.

The pathogenesis of

P. aeruginosa can be divided into three stages: bacterial
attachment and colonization, local invasion, and dissemination
with systemic disease (Odeh & Quinn, 2000).

It remains an

effective and lethal bacterium due to its resistance to many
antibiotics and antimicrobial treatments.

P. aeruginosa is one

of few nonfermentative bacteria that falls into each of the
three classes of antibiotic resistance; intrinsic resistance,
acquired resistance, and genetic resistance.

Intrinsic

resistance consists of the resistance that occurs on the average
strain of a given species without antibiotic exposure.

Acquired

resistance is observable when a strain gains resistance but has
no genetic alteration.

Genetic resistance involves the stable

acquisition of new genetic material, either through mutation of
an existing gene product or through gaining of a drug resistance
plasmid (Hancock, 1998).
As a Gram-negative bacterium, P. aeruginosa possesses
lipopolysaccharide (LPS) in its outer membrane.

LPS, as shown

in figure 1, is a nonpilus adhesin which is composed of a
hydrophobic lipid A region, a hydrophilic core region, and then
a series of O-specific repeating sugars that provides protection
and antigenic variability for the bacterium during an infection.
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The lipid A portion of LPS secures P. aeruginosa to the host and
is the toxic component of LPS.

LPS attaches to cystic fibrosis

transmembrane conductance regulator (CFTR) which is a chloride
channel protein.

Studies have shown that the attachment of CFTR

to LPS causes CFTR to initiate the innate or natural immunity
(Schroeder et al., 2002).

When a patient has cystic fibrosis,

the lipid A structure can influence two parts of the
pathogenesis.

First, it is able to enhance bacterial survival

or colonization due to the resistance lipid A gives against
cyclic adenosine monophosphates (cAMP) and other membrane active
components of the innate immune system.

Secondly, on the other

end of the spectrum, lipid A is also known to begin an
inflammatory response with specific CF lung (Ernst et al.,
1999).
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Figure 1: The structure of LPS

O-antigen
repeating subunit
Polysaccharide
Lipid A
Outer membrane
Peptidoglycan
(Periplasm)
Cytoplasmic
membrane

P. aeruginosa has many exotoxins to harm the host cells.
ExoS has ADP-ribosylating activity for a number of host cell
proteins including the intermediate filaments of cytoskeleton
and GTP-binding proteins which are involved in host cell signal
transduction systems.

ExoS is delivered to the host cells

through the type III secretion system.

Cytotoxin ExoS has two

functional domains which aid in its toxicity.

Intracellular

expression of the amino-terminal domain causes disruption of
actin while the expression of the carboxyl-terminal domain has
FAS-dependent ADP-ribosyltransferase activity and is cytotoxic
to eukaryotic cells (Pederson et al., 1999).

ExoS has been

found to cause the induction of the apoptotic pathway in
epithelial and fibroblast cell lines (Kaufman et al., 2000).
9

ExoT, another of the exoenzymes, has been found to have a lower
molecular weight than ExoS even though it possesses the same
function as ExoS (Liu et al., 1997).

The final two exoenzymes,

ExoU (Finck-Barbancon et al., 1997) and ExoY (Yahr et al.,
1998), have unclear functions and mechanisms at this time.
Another toxin that is secreted using type II secretion by
P. aeruginosa is exotoxin A.

Similar to exoenzyme S, exotoxin A

ADP-ribosylates elongation factor-2, which is essential in
protein synthesis.

After binding to the 300kDa glycoprotein

receptor, the enzymatic portion is internalized by endocytosis
which then causes negative effects on the host cell.

Exotoxin A

is thought to be the most toxic virulence factor produced by P.
aeruginosa.

However, studies are finding the polyclonal and

monoclonal antibodies to small areas of exotoxin A can aid in
passive immunization or topical treatment of burn patients
(Elzaaim et al., 1998).
Among the virulence factors that allow P. aeruginosa the
ability to cause invasive disease are extracellular proteases.
There are various proteases that inhibit the function of
neutrophils, monocytes, natural killer cells, T-cells, and
inactivate complement and immunoglobulins.

The two main

proteases, elastase and alkaline protease, facilitate
necrotizing infections and have the ability to cause
inactivation of human gamma interferon and tumor necrosis factor
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(Odeh and Quinn, 2000).

Elastase promotes intra-alveolar

hemorrhage and necrosis by solubilization of elastin-containing
human lung tissue and degradation of laminin and elastin
vascular tissue.

Monoclonal antibodies have been developed

against P. aeruginosa for two different epitopes in which either
will neutralize proteolytic activity (Kooi et al., 1997).
Alkaline protease is the other main protease that is
secreted by P. aeruginosa (Cryz and Iglewski, 1980).
to destroy nonspecific host defenses.

It is able

Alkaline protease has

been associated with corneal infections due to P. aeruginosa.
Isogenic mutants that possessed no alkaline protease were
created.

These mutants were still able to establish corneal

infections, so therefore alkaline protease is not needed in the
pathogenesis of P. aeruginosa keratitis (Pillar et al., 2000).
The hemolysins produced by the bacterium are phospholipase
C (PLC) and rhamnolipid.

PLC, an alkaline protease, is able to

degrade the surfactant of the lung.

PLC is able to

hydrolytically degrade lecithin and phosphatidylcholine.
Lecithin is an important lipid component of cell membranes which
could cause cell lysis.

Phosphatidylcholine is a major

component of lung surfactant (Lema et al., 2000).

Without this

protective surfactant film, fluid in the lungs could block small
airways and inhibit proper airflow.

For a cystic fibrosis

patient, the lungs are left much more susceptible to invasion of

11

infection and bacteria (Lema et al., 2000).

Rhamnolipid, the

other hemolysin, is also thought to aid PLC in the breakdown of
lung surfactant by solubilizing the phospholipids (Liu, 1974).
Rhamnolipid may also play a role in inhibiting the chemotactic
response of poly-morphonuclear leukocytes (PMNs) during a P.
aeruginosa infection (Doring et al., 1989).
An interesting and unique virulence factor of P. aeruginosa
is alginate.

Alginate is a linear polymer of β(1→4)-linked D-

mannuronic and C-5 epimer L-guluronic acid that forms a viscous
gel around the bacteria.
for lung infections.
against phagocytosis.

Alginate is a very important factor

It aids in the protection of the bacterium
Once P. aeruginosa has this alginate

barrier, it is practically impossible for antibiotics or
surfactants to get across (Fick, 1993).

Studies have shown that

mucoid (alginate-producing) organisms have a selective advantage
in their ability to adhere to cilia of the tracheobronchial
(Baker and Svanborg-Eden, 1989).

This selective advantage is

shown by the number of casualties of cystic fibrosis patients
infected with mucoid strains of P. aeruginosa.
P. aeruginosa also possesses a flagellum which allows the
bacterium to be motile.

Motility has a large impact on

virulence of the pathogen.

The flagellum enables the bacterium

to be more invasive than the non-flagellum strains (Feldman et
al., 1998).

It seems that the FlhA component of the flagellum
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assembly apparatus has a primary role in bacterial
internalization (Fleiszig et al., 2001).
can provide benefits to the host as well.

However, the flagellum
Studies have shown

human antiflagellar monoclonal antibodies can decrease the
in vitro motility of P. aeruginosa and can reduce its in vivo
pathogenicity when administered either before or after bacterial
challenge (Landsperger et al., 1994).

In addition, the presence

of the flagellum seems to be a key factor in the stimulation of
nonopsonic phagocytosis of the bacterium by macrophages and
neutrophils (Mahenthiralingam and Speert, 1995).
Along with flagella, P. aeruginosa also produces somatic
pili, which are also known as fimbrae, and conjugative pili.
Conjugative pili play an important role in the transfer of
genetic material between bacteria cells.

Somatic pili are one

of the most important virulence factors to P. aeruginosa due to
its function as the initial attachment of the bacterium to the
epithelial cell of the host.

Pili are able to participate in

biofilm formation which increases its pathogenicity.

Quorum

sensing is used by pili to aid in the formation of biofilms.
Quorum sensing signals are extracellular chemical signals that
cue cell-density-dependent gene expression.

More extensive

detail is given below to the structure and function of pili.
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D. Somatic Pili of P. aeruginosa
1. Pilus Structure and Classification
Pili are characterized as long polar, proteinaceous
filaments composed of polymers of subunits termed pilin.

They

stretch from the poles of the bacterial cell in groups of up to
thirty fibers extending at variable lengths but usually at an
average of 2.5 µm.

Pili are grouped on the basis of deduced

amino acid sequences of pilin genes and their assembly
mechanisms.

P. aeruginosa along with Neisseria gonorrhoeae,

Neisseria meningitides, Moraxella bovis, and Vibrio cholerae are
classified as type IV pili.

Type IV pili are also referred to

as N-methylphenylalanine (NmePhe) pili because NmePhe is the
first amino acid in the processed pilin subunit (Paranchych,
1990). Type IV pili consist of several thousand copies of the
15-18kDa pilin subunit.

The pilins are also composed of a

highly conserved amino acid sequence homology near the amino
terminus, a positively charged N-terminus leader peptide of sixseven amino acids, and a N-methylated phenylalanine at the amino
terminus of the mature pilin (Mattick et al., 1996).
The secondary structure of the pili exhibits a high
potential for both α-helix and β-sheet formations (figure 2).
The prediction is that there are β-sheets between residues 2-20
with two stretches of high α-helix potential at positions 1-9

14

and 16-19.

Further down the pili starting at positions 21, the

pilin protein subunits are arranged in a helical array with
approximately five subunits per turn.

The hydrophobic amino

terminus tail of the pili is kept buried within the center of
the filament (Forest and Tainer, 1997; Keizer et al., 2001).
Recent studies based on electrostatic interactions between the
globular portions of the pilin proteins previous x-ray
diffraction values have indicated that the coiled N-terminal
tail of each subunit complements each other.

Once the left-

handed helix is assembled, the outer diameter measures
approximately 52Å with an internal diameter of 12Å which is
believed to restrict DNA and/or RNA to pass through with only
the slight possibility of small organic molecules being able to
pass through.

If the pili play a substantial role in episomal

gene transfer and DNA transformation, then it is possible that
there is a different mechanism for DNA transfer than movement
through the center of the pilus (Keizer et al., 2001).

The area

of the pili subunit possessing the N-terminal is highly
conserved while the remaining two-thirds of the carboxy-terminal
is rendered highly variable with the exception of the disulfide
loop domain (Strom and Lory, 1993).

This variability in this

area is directly correlated with increased antigenic variation,
aiding P. aeruginosa in escaping host immune defenses
(Paranchych, 1990).
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To understand more on the assembly of the type IV pili,
researchers felt they needed to focus on providing structural
information.

In 2000, Hazes et al. studied P. aeruginosa PAK

pilin by using x-ray and EM analysis to close the gaps on
structural information.

They identified a novel protein fold

for the Type IVb pili TcpA and established the extended Nterminal α helix and central α/β scaffold as conserved features
of the Type IV pilins (Hazes et al., 2000).
Figure 2: P. aeruginosa pilin subunit (Hazes et al., 2000)

2. Pilus Synthesis, Assembly, and Regulation
There are at least 35 genes involved in the creation of
Type IV pili (McBride, 2001).

There are three NTP binding
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proteins required for the assembly and function of pili.

PilU

and PilT, two NTP binding proteins, are hyperpiliated and
produce non-motile cells when they are mutated.

These results

indicate that they are involved in providing energy for
retraction.

A mutation in PilB, the third NTP binding protein,

causes nonpiliated cells indicating that PilB provides energy
essential for assembly (Bardy et al., 2003).
The single structural pilin protein is PilA. pilA is
transcriptionally regulated by alternative sigma factor, σ54,
which is coded for by the rpoN gene (Ishimoto and Lory, 1989).
PilA, produced by pilA, is initially made as a prepilin with a
six amino acid leader peptide which will be cleaved by PilD.
PilD is a bifunctional enzyme responsible for N-terminal
processing of the prepilin and for methylation of the N-terminal
amino acid of the mature protein (Alm and Mattick, 1997).
Although recent mutational studies have shown that the lack of
methylation of pilin monomers does not appear to inhibit proper
pilus functioning, the peptidase function of PilD is essential
to P. aeruginosa (Pepe and Lory, 1998).
PilQ, another essential component for the pilus, is a 77kDa
protein that forms multimeric, outer membrane pore complexes
(Bitter et al., 1998).
outer membrane.

It allows Type IV pili to cross the

Mutations in pilQ yield a non-pilated phenotype
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with a lack of twitching motility and pilus-specific phage
resistance (Martin et al., 1995).
3. Pilus Function
The somatic pili of P. aeruginosa exhibit many functions
for the bacterium.

An important and primary function of pili is

twitching motility where the bacterium is moving across the
surface (Bradley, 1980).

Twitching is seen at the agar plate

interface where the stab inoculation represents the starting
point for the bacterium.

The bacterium can reach a ~2cm

diameter after an overnight incubation (Mattick et al., 1996).
Twitching motility is accomplished by the extending and
retracting of the pili.

Merz et al. gave strong proof of this

idea when he and colleagues used laser tweezers to show the
retracting properties of Type IV pili.

When cells were held

near the microcolony with these laser tweezers, retractile
forces pulled the cells toward the microcolony.
this fact with quantitative experiments.

They confirmed

Immobilized bacteria

with Type IV pili would bind to latex beads and pull the beads
from the tweezers.

Overall, the Type IV pili showed that they

generated substantial force and are able to directly mediate
cell movement (Merz et al., 2000).

Twitching motility was

directly observed by fluorescence microscopy in 2001 (Skerker
and Berg, 2001).

Experiments done by Maier et al. (2002)

suggest that PilT is an active motor molecule and a single motor
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complex.

It is able to power the retraction of a single pilus

with a force in excess of 100pN which would make PilT the
strongest molecular motor thus far (Maier et al., 2002).
Bacteriophage sensitivity also utilizes the retraction and
extension of the pili.

P. aeruginosa pili operate as receptors

for many phages, including PO4, PE69, and PP7 (Bradley, 1980).
Phage infections can occur when the pili attach to the phages
and retract, therefore, allowing them to come into close
distance of the bacterium (Bradley, 1972).

Transduction can

allow new genetic material to be introduced into P. aeruginosa
by having the phages in close proximity to the bacterium.
Another important function of pili is the ability to form
biofilms.

Biofilms are described as an arrangement of

microcolonies on biotic or abiotic surfaces (O’Toole and Kolter,
1998).

P. aeruginosa biofilms are formed when the bacteria come

into contact with a host surface and attach to it using various
adhesins, including flagella, Type IV pili, and fimbriae.
Biofilms are a main cause of death in cystic fibrosis patients
due to the ability for the bacteria to survive in the lung and
the secreted toxins and enzymes produced which do extensive
damage to the lungs.

Recent studies have shown that rhamnolipid

synthesis by P. aeruginosa is vital to the development and
architecture of biofilms produced in the lungs of patients
(Davey et al., 2003).
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Quorum sensing is used to assemble biofilms.

The quorum

sensing signals are extracellular chemical signals that prompt
cell-density-dependent gene expression.

The biofilms that are

assembled using quorum sensing are very dense and much harder to
disrupt (Donabedian, 2002).

Current research shows that quorum

sensing may be able to serve as a biomarker in screens to
identify agents that interfere with biofilm development (Singh
et al., 2000).
The pili are used as adhesins for the initial anchoring to
host tissue and specific receptors.

Pili promote adherence to

human epithelial cells, however more readily adhere to
epithelial cells of immunocompromised individuals (Paranchych,
1990). Specifically, the ligand for the initial anchoring is the
disulfide loop exposed only at the pilus tip (Irvin et al.,
1989).

This area on the pilus is thought to be the epithelial

cell binding domain, which is the point of attachment (Farinha
et al., 1994).

Once the pilus has bound to the receptor on the

host cell, then the pilus uses its retractable qualities to
bring it closer to the host cell.

After the bacterium is in

considerably close range to the host cell, other adhesins are
allowed to take over and attach the bacterium to the cell which
will lead to the formation of a microcolony.
The pilus can also attach to phagocytes which is a very
important function when studying the success of vaccines against

20

the bacterium.

Studies have shown that pili do serve as opsonic

phagocytosis enhancers.

This means that pili can increase the

uptake of P. aeruginosa by fibronectin-stimulated macrophages
(Kelly et al., 1989).

So, a vaccine against P. aeruginosa would

not need to be as concentrated since the body can rid itself of
a small amount of the bacteria.

Recently, it has been found

that the rpmA gene, which is used in flagellar movement, is
required for the efficient ingestion of P. aeruginosa by
macrophages (Simpson and Speert, 2000).

Flagella have been

shown to play a role in certain types of infections caused by P.
aeruginosa which would allow the bacteria to be in closer
proximity to the macrophages.

This is a very important concept

when studying a possible vaccine against P. aeruginosa since
macrophages are able to begin clearing the bacterium from the
infection site.
E.

Glycosylation of Pili

1. Identification of the Glycosylation
The study of glycosylation in prokaryotes is relatively new
to the science world even though glycosylation in eukaryotes is
very well documented.

Castric and Deal (1994) found that when

the pilin genes were sequenced from P. aeruginosa, there were
two distinct groups that became apparent based on the primary
amino acid structure.

Each strain showed a high conservation of

sequence near the 5’ end, but greatly differed at the 3’ end of
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the gene.

The two groups showed differences in that group I had

a large open reading frame (ORF), later named pilO, downstream
from pilA and a ribosome binding site while group II only had
the pilA gene followed by tRNAThr gene (figure 3) (Castric,
1995).
Figure 3: Schematic drawing of the Group I and II operons.
pilA

tRNAThr

pilO

Group I
operon
pilA

tRNAThr

Group II
operon

The predicted amino acid structure of pilO shows nine
highly hydrophobic regions.

This structure analysis implies

that the pilO gene is in a membrane, most likely in the
cytoplasmic membrane.

To confirm these findings, a pilO

deficient mutant was constructed by gene replacement technique.
The mutant was shown to make functional non-glycosylated pili
(Smedley, 2001).
2. Glycan Structure
P. aeruginosa 1244 pilin glycan is an O-linked
trisaccharide covalently attached through the β-carbon of a
serine residue at the C terminus of pilin with a ratio of one
glycan per pilin subunit (figure 4).
glycan on the fiber is unknown.

The exact location of the

A characteristic of the Type IV
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pili is the presence of a disulfide loop (DSL) adjacent to the
carboxy-terminus.

The DSL is important in pilus-mediated

adhesin (Lee et al., 1994) and is a dominant B-cell epitope for
P. aeruginosa 1244 pilin (Comer et al., 2002).

Lee et al.

(1994) have shown that the DSL is surface-located only at the
pilus tip.

The proximity of the pilin glycan to the DSL brings

into question its location on the pilus fiber.

The glycan may

be evenly distributed over the fiber or concentrated at the
pilus tip.
The determined mass of the glycan is 666.5, which correlates
with the excess mass of pilin after the value of pilA gene is
subtracted (Castric et al., 2001) The structure of the glycan
was found to be identical to the O-antigen repeating unit in LPS
(see figure 1 for the LPS structure).

This idea suggests that

pili glycosylation and the addition of O-antigen layer of LPS
are derived from the same pathway (Castric et al., 2001;
DiGiandomenico et al., 2002).

Mutants defective in the O-

antigen biosynthetic pathway were unable to glycosylate pilin
(DiGiandomenico et al., 2002).

It was also found that

glycosylation process was very non-specific with regards to
glycan source.

For example, expression of cloned O-antigen

biosynthesis gene clusters from E.coli resulted in production of
pili glycosylated with E. coli antigen (DiGiandomenico et al.,
2002).

The glycan along with the pilin DSL region, is shown to
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be an important B-cell epitope (Comer et al., 2002).

This is of

particular interest to a potential vaccine because the pilin
glycan of this bacterium produces antibodies that recognize P.
aeruginosa 1244 LPS.

Figure 4: The aminoglycan structure from P. aeruginosa 1244
pilin. (Castric et al, 2001) This is a product of total
proteolysis and it is composed of three sugars and a serine.

3. Function of the Glycan
Although studies have shown that the glycan does exist on
P. aeruginosa 1244 pili, the function has not yet been
determined.

Possible functions could include blocking the

binding of complement proteins or masking the epitope for antipilus antibodies.

If it is evenly distributed along the pilus,

then it could aid in increasing the amount of twitching motility
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and biofilm formation (Castric et al., 2001).

If the glycan is

present over the entire surface and possesses a negative charge,
it may alter the interactions between the pili and the external
structures causing increased twitching motility and biofilm
formation.

4. Potential Vaccine Using the Glycan
Of particular interest to a possible vaccine design, is
that the glycan stimulates antibodies to recognize LPS from P.
aeruginosa (Comer et al., 2002).

Therefore, these glycosylated

pili have the potential to serve as a vaccinating agent in which
the glycan is the epitope and the bacterial LPS is the immune
response target.

F. Thesis Goals
The objectives of this research thesis project are as
follows: [1] To provide direct microscopic evidence for the
surface location of the pilus glycan [2] to determine the rabbit
antibody response by immunization with pure LPS-free pili as
well as to demonstrate that protective antibodies produced in
response to the pilin glycan target the pathogen LPS [3] to
determine an optimal immunization protocol for a long term
protection study in the murine model and [4] to determine
whether or not the antibodies in the serum from rabbits that
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were immunized with pure LPS-free pili could enhance killing of
the bacteria by the PMNs which would also reveal if phagocytosis
was due to a pilus-specific or LPS-specific response.
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II. Materials and Methods
A. Bacterial Strains
Table 1 comprises a list of all bacterial strains that were
used in this work.

A brief description of each bacterial strain

is included.
Table 1:

Bacterial Strains used in this Work

Bacterial
strains
P. aeruginosa
1244
P. aeruginosa
1244G7
P. aeruginosa
1244.47
P. aeruginosa
wbpL
E. coli HB101

Description

Selectable
Marker

Reference

Wild-type, produces
glycosylated pili and
flagella,serogroup
O7strain
PilO-, allelic
replacement mutant of
PA1244

None

Castric et al.,

Gmr

Smedley, 2001

Transposon
inactivation of pilA
and pilO genes of PA
1244
No LPS and
nonglycosylated pili

Hgr

Castric
Unpublished

Gmr

DiGiandomenico et

Highly transformable
strain

None

1989

al., 2002
Sambrook et al.,
1989

B. Bacteriological Media and Growth Conditions
All cultures were grown in LB (Luria Bertani) broth or on
LB agar plates (pH 7.3) at 37oC for approximately 14 hours,
unless otherwise noted.

The broth cultures were vigorously

shaken overnight.
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C. Pili Preparation
Ten milliliters of LB broth was inoculated with the
specific strain of P. aeruginosa to be tested.

This was

incubated overnight at 30oC with agitation of 250rpm.

The foil

covered 70cmx30.5cmx3cm metal culture pans and 500ml CAYE media
(3.75g of Casamino acids, 0.75g yeast extract, 10g of agar, and
0.5L deionized water) in 1L flasks were sterilized by
autoclaving.

The CAYE medium was cooled to 45oC and poured into

the sterilized metal pans.

When the agar had solidified, 2.5-

3ml of the overnight was added drop wise to the agar surface and
spread evenly with a sterile hockey stick shaped glass rod over
the entire surface.

The foil top was replaced and the

inoculated medium was incubated at 37oC for 14-16 hours.

A

sterile flat sharp blade with a handle similar to a paint
scraper was used to loosen the cells from the culture surface
and a sterilized cotton-tipped applicator was used to transfer
the cells from the blade to 100ml of 40mM NaPB.

The suspension

was stirred vigorously for 30 minutes at room temperature.
After the cells were transferred to a 250ml centrifuge tube,
they were spun in the centrifuge at 16300 xg in the GSA rotor
for 30 minutes.

After discarding the pellet, the supernatant

was measured and the final concentration was adjusted to contain
3% polyethylene glycol (PEG as described by Silipigni-Fusco,
1987) and 0.5M NaCl of the final volume while stirring at room
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temperature (Silipigni-Fusco, 1987).

Once all of the components

were in solution, the tube was left on ice for two hours.

The

suspension was spun (GSA rotor) as before and the pellet was
taken up in the original volume of 100ml of NaPB.

After

stirring this solution for one hour at room temperature, it was
spun (GSA rotor) as before and the pellet was discarded.
PEG/NaCl was added to the supernatant and spun (GSA rotor) as
before.

The pellet was resuspended with approximately 5ml of

NaPB and divided among four microfuge tubes.

The solution was

spun in a microfuge at maximum speed for 5 minutes and the
pellet was discarded.

In a new microfuge tube, 0.3ml of 15%PEG

and 2.5M NaCl was added to precipitate the supernatant and then
stored on ice for 30 minutes.

After spinning in the microfuge,

the tube was drained completely and the precipitate was stored
at 4oC.

These pili were used for the electron microscopy work,

however the pili were further purified for the vaccine studies.
D. LPS Extraction
LPS was extracted from bacterial strains using a method
described by Hitchcock and Brown (1981).

Two milliliters of

cells from an overnight broth culture was pelleted, drained, and
resuspended with 200µl of 1X SDS loading buffer (50mM Tris/HCl pH
6.8, 100mM DTT, 2% SDS, 0.01% bromophenol blue, 10% glycerol,
and 0.001% β-mercaptoethanol).

The sample was heated at 95°C for
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10 minutes, followed by treatment with 25µg of proteinase K for
one hour at 60°C.
E. Transmission Electron Microscopy (TEM)
Micrographs from the transmission electron microscope were
produced by preparation of copper grids with P. aeruginosa from
the overnight culture.

This organism was plated on CAYE plates

for optimum pili production overnight (14 hours) at 37oC.

The P.

aeruginosa strains that were used in this experiment were 1244
and 1244G7.

The bacteria was transferred to 1ml of filter-

sterilized Phosphate Buffer Saline (PBS) (5.3L deionized H2O, 28g
NaCl, 0.7g KCl, 4.0g Na2HPO4, 0.35g CaCl22H2O, 0.53g MgCl26H2O) by
a sterile swab and twirled carefully to minimize the amount of
damage to the pili.

A drop (approximately 100µl) of P.

aeruginosa and PBS mixture was placed on parafilm and the dull
side of a formvar-coated copper grid from Electron Microscopy
Sciences (Fort Washington, PA) was placed on the drop for two
minutes at room temperature.

The grid was blotted on filter

paper by touching the shiny side to the paper and allowing the
liquid to run through the porous grid.

In most cases, the grid

was fixed at room temperature for 5 minutes with cryofix, which
consists of 2% paraformaldehyde and 0.01% glutaraldehyde in PBS.
This material was dispensed in a 20ml syringe with a 0.2µm
syringe filter.

The grid was then washed with PBS three times
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for 5 minutes each by placing the grid topside down on a drop of
PBS at room temperature.

The PBS was dispensed from a 20ml

syringe with a 0.2µm syringe filter. The method of placing the
grid topside down on a reactant was continued throughout the
entire experiment at room temperature.

A follow-up washing with

BSA solution was used three times at 5 minutes per wash.

The

BSA solution consists of 0.5% BSA (bovine serum albumin) and
0.15g of glycine in 100µl of PBS and was dispensed in a 20ml
syringe with a 0.2µm syringe filter.

The grid was put into

normal goat serum at a dilution of 1:20 BSA solution for 30
minutes and then washed with BSA solution three times for 5
minutes each.

The primary antibody was diluted with 1:1000 in

PBS and the grid was placed on the primary antibody drop for 60
minutes.

Another washing with BSA solution was done three

times at 5 minutes each time.

The grid was now prepared for the

secondary antibody which was diluted to 1:25 BSA solution.
Amersham Biosciences (Piscataway, NJ) AuroProbe 5nm gold labeled
goat anti-mouse IgG was used in this experiment.

The secondary

antibody was incubated on the grid for 60 minutes.

The grid was

washed with BSA solution three times for 5 minutes each and PBS
three times for 5 minutes each.

The entire grid was fixed in

2.5% glutaraldehyde from Sigma (St. Louis) for 5 minutes.
was dispensed in a 20ml syringe with 0.2µm syringe filter.
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It
The

grid was washed in PBS for 5 minutes and then washed in
sterilized distilled water for 1 minute.

Sigma (St. Louis) 2%

phosphotungstic acid diluted in deionized water, pH 6 was
applied to the grid for a second and the grid was allowed to dry
before putting it in the storage case.

Pictures were taken at

the Cell Biology and Physiology Department at the University of
Pittsburgh with the aid of Dr. Donna Stolz.

A JEM 1210 Computer

Controlled High Contrast 120kV TEM was used.

Pictures taken

were chosen as a representative field of what was being viewed
on each grid.

The negatives were developed by standard methods

of 4 minutes in developer, 1.5 minutes in water rinse, 2.5
minutes in fixer, 20 minutes in water rinse, and 1 minute in
Kodak picture protector.

The negatives were printed on the

Saunders/LPL Super Dichroic 4500II and Rapidoprint DD3700.
F. Scanning Electron Microscope (SEM)
P. aeruginosa was plated on CAYE plates for optimum pili
production overnight (14 hours) at 37oC.

The P. aeruginosa

strains used in this experiment were 1244 and 1244G7. The
bacteria was transferred to 1ml of filter-sterilized PBS (5.3L
deionized H2O, 28g NaCl, 0.7g KCl, 4.0g Na2HPO4, 0.35g CaCl22H2O,
0.53g MgCl26H2O) by a sterile swab and twirled carefully to
minimize the amount of damage to the pili.

Round 12mm cover

slips were spread with 0.2µl of CellTak obtained from
Collaborative Biomedical Products (Bedford, MA) and allowed to
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dry overnight at room temperature.

Excess CellTak was drawn off

the cover slips with filter paper on the following morning to
ensure a dry surface.

Approximately 100µl of bacteria cells were

added to each cover slip and incubated for 10 minutes at room
temperature.

The cells were fixed with 2% paraformaldehyde from

Sigma (St. Louis) in PBS for ten minutes.

Excess

paraformaldehyde was drawn off with filter paper.

The round

12mm cover slips were placed cell side up into non-sterile 24
well tissue culture plates.

The cover slips were washed in PBS

three times for five minutes each and then washed in BSA (PBS
containing 0.5% BSA and 0.15% glycine) three times for five
minutes each.

The washing solutions, the antibodies, and the

glutaraldehyde were added respectively to the wells of the
tissue plate and allowed to incubate.

Removal of there

materials from the tissue plate was done using a Pasteur
pipette.

Normal goat serum diluted 1:20 in the BSA solution was

used for 45 minutes at room temperature to block the cells.
Three BSA washings for five minutes each followed.

The primary

antibody, 11.14, was added to the sample for two hours at room
temperature followed by six washings of BSA for five minutes
each.

The secondary antibody, goat anti-mouse conjugated to

15nm gold particles, was obtained from Amersham Biosciences
(Piscataway, NJ).

It was diluted to 1:25 in the BSA solution

and left on the cover slips overnight at 4oC.
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Three washings

each with the BSA solution and PBS for five minutes followed.
The cover slips were fixed in 2.5% glutaraldehyde in PBS for one
hour at room temperature and then washed with PBS three times
for five minutes each.

A graded series of dehydrations with

ethanol was completed to remove all of the water in the sample.
The samples were critically point dried using Emscope 750
critically point dryer and then over coated with vaporized
carbon using a Cressington 108Carbon/A carbon coater.

Cells

were visualized using a JEOL-JEM-6335F field emission gun
scanning electron microscope at the University of Pittsburgh
with the aid of Dr. Donna Stolz.

Field emission backscattered

electron and standard secondary electron digitized images were
taken in tandem to identify areas of gold labeling on the cell
surface.
G. Vaccine Preparation
The purification procedure here is a modified version
(Castric, 1995) of a previously described protocol (SilipigniFusco, 1987).

Strain 1244N3, a mutant that is unable to make

pilin, could produce glycosylated strain 1244 pilin by carrying
pPAC46.

pPAC46 is a plasmid that contains strains 1244 pilA and

pilO genes under the control of a tac promoter.

Glycosylated

pili produced by hyperexpression of pilA gene of pPAC46 were
isolated and purified as described above.

This protocol

produced 10-20mg of pili per liter of culture with traces of
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LPS.

To rid the sample of LPS contamination, the pili were

subjected to gel filtration and chromatofocusing in the presence
of the detergent β-octyl glucoside (βOG).

A 6.12mg glycosylated

pilin prep was suspended in 700µl of a solution containing 25mM
Bis-Tris/HCl (pH 7.0), 1% βOG, and 0.02% sodium azide and
incubated at 24oC for 30 minutes.

After being microcentrifuged

briefly, the supernatant fluid was applied to a Superose 12
Column (1.0 by 30cm) that had been equilibrated with the same
buffer solution.

Two hundred and fifty microliter aliquots were

taken at a flow rate of 0.5 ml/min.
determined by the A280.

The major peak was

This material was applied to a Mono P

anion-exchange column (0.5 by 10cm) that had been equilibrated
with 25mM Bis-Tris (pH 6.25) containing 0.02% sodium azide.
Pilin monomer was removed by the addition of a solution
containing 10% Polybuffer 74 (pH 4.0), 1% βOG, and 0.02% sodium
azide.

A flow rate of 1.0ml/min and 0.5ml fractions produced a

single peak which was identified at A280.

It was pooled and

dialyzed twice against one liter of 5mM Bis-Tris (pH 7.0), which
allowed reaggregation of the pilin subunits.

To test for the

presence of LPS, approximately 200µg of reaggregated pilin was
proteolytically digested by a protocol established by Hitchcock
and Brown (1983).

A Western blot with LPS-specific monoclonal

antibody 11.14 was used to analyze the pilin.
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The standard was

known amount of P. aeruginosa 1244 LPS, either analyzed
separately or added to aliquots of digested pilin.

LPS, if

present, was below the level of the lowest standard used meaning
that any LPS was present at a concentration of less than of
0.5ng of LPS/µg of pilin.
H. Rabbit Immunization
1. Antibody Production
All animal work was completed under the rules and
regulations of the IACUC.

This procedure was carried out by

Covance Research Products in Denver, PA. The lyopholized pili
protein (1.15mg/ml) was resuspended in 1ml of saline.

Two NZW

female rabbits were injected with pure LPS free pili and bled
every three weeks to determine antibody levels.
can be found in Table 2.
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The protocol

Table 2: Antibody Production Timeline.
injected with pure LPS-free pili.

Day
(1)
12-10-02

(21)
12-31-02

(31)
1-10-03
(42)
1-21-03
(52)
1-31-03
(63)
2-11-03
(73)
2-21-03
(84)
3-04-03
(94)
3-14-03
(105)
3-25-03
(115)
4-04-03
(118)
4-08-03

Two rabbits were

Procedure
Prebleed of 5ml of serum
Injected intradermally in the back at multiple
sites with a total of 250µg of pili protein
with adjunct Freund’s Complete Adjuvant (FCA)
(434µl of pili + 1ml saline + 1ml FCA)
Boost subcutaneous and intramuscular: total of
125µg of pili protein with adjunct Freund’s
Incomplete Adjuvant (FIA)
(217µl of pili + 1ml saline + 1ml FIA)
Test Bleed of approximately 5ml of serum
Boost subcutaneous in the rear flanks: total of
125µg of pili protein with adjunct FIA
(217µl of pili + 1ml saline + 1ml FIA)
Test Bleed of approximately 5ml of serum
Boost subcutaneous in neck: total of 125µg of
pili protein with adjunct FIA
(217µl of pili + 1ml saline + 1ml FIA)
Production Bleed of approximately 20ml of serum
Boost subcutaneous dorsal: total of 100µg of
pili protein with adjunct FIA
(173µl of pili + 1ml saline + 1ml FIA)
Production Bleed of approximately 20ml of serum
Boost subcutaneous in the neck region: total of
100µg of pili protein with adjunct FIA
(173µl of pili + 1ml saline + 1ml FIA)
Production Bleed of approximately 20ml of serum
Terminal Bleed of approximately 50ml of serum
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2. Serum Storage
Four-milliliter aliquots of these sera were placed in glass
screw top containers and stored at –20oC.
I. Mouse Immunization
1. Immunization Protocol
The protocol employed was approved by the Duquesne University
Animal Safety Committee, and all procedures required by the
Committee were followed.

For this study, thirty 6-8 week old

balb-c female mice (20-25g) were obtained from Hilltop Lab
(Scottdale, PA).

Each in their own cage, the mice were left

undisturbed in a non-sterile environment at Duquesne University
Animal Care Facilities for five days prior to the beginning of
the experiment.

Introduction of the vaccine into the mice by

the respiratory route was utilized due to its painless manner
and its ability to raise mucosal response.

Immunization was

carried out on anesthetized (0.25cc Ketamine/xylazine) animals.
Each animal received 10µl of a sterile solution containing 5, 10,
or 20µg of pure reaggregated P. aeruginosa 1244 pili into each
nare.

Sham immunized animals only received sterile PBS (5.3L

deionized H2O, 28g NaCl, 0.7g KCl, 4.0g Na2HPO4, 0.35g CaCl2-2H2O,
0.53g MgCl2-6H2O), 10µl per nare.

Respiration resulted in the

aerosolization of the pili with the deposition of the sample in
the animal’s lungs.
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2. Sampling Procedures
Three types of samples were taken for determination of
pilin and LPS-specific antibodies: serum, bronchial lavage, and
fecal.

Serum samples were taken by cardiac puncture from

animals anesthetized with a double dose of (0.50cc)
ketamine/xylazine.

The animal was placed in dorsal recumbency

and the needle (TB syringe) was inserted to the left of the
midline at the base of the sternum.

Once blood flowed into the

hub of the needle, the sample was drawn.
euthanasia by exsanguination.

This resulted in

After placing the serum sample in

the refrigerator overnight, serum extraction was completed by
spinning at 5000 rpm the following morning for 90 seconds.

The

serum was then drawn off of the whole blood cells and placed in
a 1.8ml cryotube from Nunc (Denmark) for storage at –20oC.
Bronchial lavage (BAL) was carried out on the same animal.
The trachea was exposed with a scissor cut below the chin, which
was followed by removal of surrounding tissue with forceps.
exposed trachea was cut half-way through with scissors.

The

A 1 ml

syringe of PBS (5.3L deionized H2O, 28g NaCl, 0.7g KCl, 4.0g
Na2HPO4, 0.35g CaCl22H2O, 0.53g MgCl26H2O) with a 20gauge 1.16IN
1.1 x 30 mm Angiocatheter (Becton Dickinson; Swedesboro, NJ) at
the end was slowly ejected into the lungs and drawn back into
the syringe, therefore producing the lavage sample.

The samples

were stored in –20oC in 1.8ml cryotubes from Nunc (Denmark).
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Fecal pellets produced by each animal were collected.
These were then weighed to 0.05g and suspended in 300µl of killer
filler (200ml of 0.1M NaOH supplemented with 10g of casein and
added to 1.8L of Phosphate Buffer Saline (PBS) [5.3L deionized
H2O, 28g NaCl, 0.7g KCl, 4.0g Na2HPO4, 0.35g CaCl2-2H2O, 0.53g
MgCl2-6H2O] containing 10g of bovine serum albumin.

The pH of

the solution was adjusted to 7.4, followed by the addition of
0.2g of phenol red and 3.6g of sodium azide [Lynette Young of
the Walter Reed Army Institute of Research, personal
communication]).
fluid saved.

The sample was centrifuged and the supernatant

The samples were stored in –20oC in 1.8ml cryotubes

from Nunc (Denmark).
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3. Schedule of Events
Table 3: Overview of Immunization of Mice Protocol.
started at the end of the five-day adjustment period.

Day
0

3

7

10

14

Day 0

Treatment
Immunization of Animals 1-8, 5µg of reaggregated pili
Immunization of Animals 9-16, 10µg of reaggregated pili
Immunization of Animals 17-24, 20µg of reaggregated pili
Sham immunization of Animals 25-30, PBS
Sacrificed Animals 1 & 2, 5µg of reaggregated pili
Sacrificed Animals 9 & 10, 10µg of reaggregated pili
Sacrificed Animals 17 & 18, 20µg of reaggregated pili
Sacrificed Animals 3 & 4, 5µg of reaggregated pili
Sacrificed Animals 11 & 12, 10µg of reaggregated pili
Sacrificed Animals 25 & 26, 20µg of reaggregated pili
Sacrificed Animals 25 & 26, PBS
Immunization of Animals 5-8, 5µg of reaggregated pili
Immunization of Animals 13-16, 10µg of reaggregated pili
Immunization of Animals 21-24, 20µg of reaggregated pili
Sham immunization Animals 27-30, PBS
Sacrificed Animals 5 & 6, 5µg of reaggregated pili
Sacrificed Animals 13 & 14, 10µg of reaggregated pili
Sacrificed Animals 21 & 22, 20µg of reaggregated pili
Sacrificed Animals 7 & 8, 5µg of reaggregated pili
Sacrificed Animals 15 & 16, 10µg of reaggregated pili
Sacrificed Animals 23 & 24, 20µg of reaggregated pili
Sacrificed Animals 27-30, PBS

Antibody capture ELISA test were carried out using
lipopolysaccharide from P. aeruginosa 1244 as the antigen and
dilutions of the mouse samples as the primary antibody.
Antibody types were determined using alkaline phosphataselabeled secondary antibodies specific for heavy chain type.
ELISA protocol is outlined below.
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The

J. Immunological Assays
1. Capture ELISA
A Fisherbrand Clear non-sterile polystyrene 96-well ELISA
plate from Fisher Scientific (Pittsburgh, PA) was obtained for
these experiments.

Each of the samples was done in triplicate

for an average value per sample.

The wells were coated with 50µl

of 1mg/1ml poly-l-lysine from Sigma (St. Louis) in PBS.

Poly-l-

lysine is a highly positive charged amino acid chain which
promotes cell adhesion.

The plate was incubated at 30oC for 15

minutes with constant motion and then washed with PBS (5.3L
deionized H2O, 28g NaCl, 0.7g KCl, 4.0g Na2HPO4, 0.35g CaCl2-2H2O,
0.53g MgCl2-6H2O) three times.

A washing with PBS consisted of

50µl of PBS per well and agitation of the contents by hitting the
plate with the palm of ones hand.

The PBS was then spilled out

and the plate was struck onto paper towels to remove excess
moisture.

The wells were coated with 50µl of 10µg/ml pure LPS

for 2 hours at 30oC with constant motion and then washed with PBS
three times.

To block the wells, 400µl of killer filler (10g

casein, 0.1N NaOH, 10g BSA, 1800ml PBS, adjust pH to 7.4, 0.2g
Phenol Red, and 3.6g Sodium Azide) was added to each well for 2
hours at 30oC with constant motion and then washed with PBS three
times.

Serum to be tested was used as the primary antibody.

Dilutions of the serum were made ranging from 102 cells/ml to
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5 x 107 cells/ml.

Each well had 50µl of the serum dilutions

added to it and incubated for 1 hour at 30oC with constant
motion.

The plate was washed three times with PBS.

Fifty

microliters of secondary antibody, a phosphatase labeled
affinity-purified antibody, was added to the wells in a 1:1000
dilution of killer filler.

The wells were incubated at 30oC for

90 minutes with constant motion and then washed three times with
PBS.

The reaction was developed using 50µl of 1mg/ml p-

nitrophenyl phosphate (pNPP) from Fisher Scientific (Fairlawn,
NJ) which was incubated at 30oC for 30 minutes with constant
motion.

The reaction was stopped by adding 50µl 0.1M EDTA from

Fisher Scientific (Fairlawn, NJ) to each well directly on top of
the pNPP.

The plate was read on an ELISA Bio-Rad Model 3550

Microplate Reader at a wavelength of 405nm.
2. Western Immunoblot Analysis
Western immunoblot analysis was used to visualize crossreactivity between pili and LPS O-antigen.

LPS and pili were

electroblotted on to 0.2-0.45µm nitrocellulose paper (Micron
Separations Inc.

Westborough, MA) by using the BioRad Mini

Trans-blot® Electrophoretic Transfer Cell as a constant voltage
of 100V for 20 minutes in a trans-blot buffer (25mM tris, 192mM
glycine, 20% methanol, approximate pH 8.3)
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Upon completion, the nitrocellulose paper was removed and
blocked overnight at room temperature with constant motion in
killer filler.

The pieces of nitrocellulose paper were treated

overnight (approximately 24 hours) with a primary antibody
solution, production bleed diluted to 1:1000 in killer filler,
at room temperature with constant motion.

The nitrocellulose

paper was then washed three times with PBS in 10-minute
intervals with constant motion.

Once the nitrocellulose paper

was washed, a phosphatase conjugated secondary goat anti-rabbit
antibody was diluted to the 10-3 with killer filler.

The

nitrocellulose paper was then incubated for 90 minutes with
constant motion.

Two washings with PBS and a washing with 50mM

tris/HCl pH 8.0 followed.

Reactions were visualized by adding a

developer solution comprised of 10mg Napthol AS-MX phosphate
(Sigma Chemical, St. Louis, MO) and 20mg Fast-Red (Sigma
Chemical, ST. Louis, MO) dissolved in 10ml 50mM tris/HCl pH 8.0
while gently shaking.

A positive reaction was denoted by the

development of red bands.

Rinsing the nitrocellulose paper with

tap water for several seconds terminated the reaction.
K. Serum Resistance Assay
Bacteria strains were grown in 10ml of LB broth for 12 hours
at 37oC with constant motion.

One hundred microliters was spread

by the hockey stick method on CAYE plates and incubated at 37oC
overnight.

After 14 hours of incubation, 5ml of LB broth was
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added to each plate and gently shaken for 5-10 minutes to loosen
the bacteria from the plate.

The mixture was transferred to a

50ml tube using a 10ml pipette to avoid damage to the pili.

In

a cuvette, the mixture was diluted to a 1:9 ratio with saline to
measure the absorbance at 650nm.

The concentration of cells was

calculated by solving the ratio 1.0A/2x109 cells/ml and adjusted
to 1 x 107 cells/ml in the sample.

The reaction 1 contained 70µl

of bacterial cells, 0µl of mouse serum, and 30µl of saline.
Reaction 2 contained 70µl of bacterial cells, 30µl of mouse
serum, and 0µl of saline.
Each reaction tube was incubated at 37oC.

At time 30, 60, and

120 minutes, 20µl of each reaction mixture was removed and
diluted in 980µl saline (10^5 cells/ml).

Subsequent dilutions

were made to the concentration 104 cells/ml and 103 cells/ml.
Reaction 1 was also completed at time 0.

Each LB plate was

inoculated with 100µl of each dilution from each reaction mixture
and spread evenly using the hockey stick method.

The plates

were incubated overnight at 37oC and the colonies were counted
and recorded the following day.
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L. Opsonization Assay
P. aeruginosa strains to be tested were grown in 5ml LB broth
for 14 hours at 37oC at 250rpm.

A secondary culture was started

by adding 100µl of the overnight culture to 5 ml of LB broth and
incubated in 37oC with constant motion.

Blood samples (from

myself) were drawn from the arm by the nursing staff at Duquesne
University.

The sample was placed in a heparinized tube on ice

to prevent clotting.

In a plastic tube, 2ml of heparinized

blood and 2ml of sterilized saline (8.5g NaCl/L) were added and
mixed by drawing the fluid in and out of a 10ml pipette.

The

blood/saline mixture was placed in a 15ml sterilized centrifuge
tube on top of 3ml of sterile Ficol-Paque Plus from Amersham
Biosciences (Piscataway, NJ) using caution to keep the two
solutions separate.

The mixture was centrifuged at 1600rpm for

30-40 minutes at 18-20oC.

The upper layer was drawn off using a

sterile Pasteur pipette, leaving the lymphocyte layer
undisturbed at the interface and the red blood cells at the
bottom of the centrifuge tube.

Using a clean sterile Pasteur

pipette, the lymphocyte layer is transferred to a clean sterile
15ml centrifuge tube.

The cells are re-suspended in 6mL of

saline by carefully drawing them in and out of a Pasteur
pipette.

The solution was centrifuged again at 2300 rpm for 10

minutes at 18-20oC.

After removing the supernatant, the

lymphocytes were re-suspended in 6ml of saline.
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The

centrifugation of the solution was repeated at 2300 rpm for 10
minutes at 18-20oC.
was removed.
saline.

The washing was repeated and the supernatant

The lymphocytes were re-suspended in 200µl of

The viable cells, which appeared larger and had a

whitish glow whereas the dead cells were withered and brown in
color, were counted using a hemocytometer under a phase contrast
scope at 400 magnification.

Cells were counted per block (area

= 4.2 x 105 mm3) and the mean was determined after approximately
600 cells were counted.
The absorbance at 650nm for the secondary bacterial culture
was found and the concentration of cells/ml was determined by
using the ratio of the known value of 1.0A/2x109 cells/ml.
concentration was then adjusted to 3 x 107 cells/ml.

The

The

bacterial cells were centrifuged and the supernatant was
removed.

The cells were then re-suspended in 1ml of saline to

eliminate contamination from the LB broth which could render the
results invalid.
Control and test solutions were prepared.

The control mixture

consisted of 100µl of bacterial cells and 300µl of saline.

The

test mixture contained 100µl of bacterial cells, 100µl human
complement, 100µl white blood cells, and 100µl rabbit serum.
These solutions were incubated at 37oC.

Aliquots were removed at

0, 30, and 60 minutes, diluted with sterile saline, and plated
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out.

The LB plates were incubated overnight at 37oC.

Cell

colonies were counted and recorded the following morning.
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III. Results
A. Electron Microscopy Results on Glycosylated and
Nonglycosylated P. aeruginosa
1.Transmission Electron Microscopy
a. Whole Cells
Previous work by Castric (1995) has shown that pili from this
organism are glycosylated but the specific location of the
glycan on the fiber remains unknown.

A characteristic of the

pilin of P. aeruginosa is the presence of a disulfide loop (DSL)
adjacent to the carboxy-terminus which is important in pilusmediated adhesin (Lee et al., 1994).

Lee et al. (1994) have

shown that the DSL is surface-located only at the pilus tip.
The proximity of the pilin glycan to the DSL brings into
question its location on the pilus fiber.

The goal of this

study is to determine whether it is evenly distributed over the
surface of the fiber or concentrated at the pilus tip.

In order

to accomplish this, whole cells and isolated pili were analyzed
using transmission electron microscopy (TEM) and scanning
electron microscopy (SEM).

The pilin saccharides were located

using a glycan-specific monoclonal antibody and visualized using
a gold-labeled secondary antibody.
Typical TEM micrographs of whole cell P. aeruginosa 1244 and
1244G7, a mutant that lacks a pilO gene and produces
nonglycosylated pilin (Smedley, 2001), can be found in Figure 5
and Figure 6, respectively.

There is no observable difference
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in length, thickness, or amount of pili observed between
glycosylated and nonglycosylated strains.

P. aeruginosa 1244

and 1244G7 cells were treated with the monoclonal glycan
specific antibody, 11.14, and a secondary antibody conjugated
with gold particles in order to determine the glycan location.
Gold labeling can be seen on the pili and on the cell surface of
1244 (Figure 7). No gold particles were seen on the flagellum
which suggests the observed reaction is not due to LPS
contamination.

There were no gold particles found on the pili

of nonglycosylated P. aeruginosa 1244G7.

But like strain 1244,

there was gold-labeling found associated with LPS on the cell
surface (Figure 8).

Of major importance was the finding that

gold labeling was seen along the entire 1244 fiber.

This

suggests that glycan is not located only at the tip of the
fiber, but over the entire pilus surface.
As a control to ensure that this procedure was working, P.
aeruginosa 1244 and 1244G7 cells were treated with secondary
antibodies in the absence of the glycan-specific monoclonal.
There were no gold particles found on either strains 1244 or
1244G7 (Figure 9 and 10, respectively).

Therefore, the glycan

specific monoclonal antibody is needed for the reaction to be
seen.
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b. Isolated Pili
To ensure that the whole cell results were not an artifact,
P. aeruginosa 1244 and 1244G7 isolated pili were also observed
with no antibody probes and with the monoclonal glycan-specific
antibody.

Typical TEM pictures of isolated pili from P.

aeruginosa strains 1244 and 1244G7 can be found in Figure 11 and
12, respectively.

There is no observable difference in length,

thickness, or amount of pili observed between glycosylated and
nonglycosylated strains.

P. aeruginosa 1244 and 1244G7 isolated

pili were treated with the monoclonal glycan specific antibody,
11.14, and the secondary antibody conjugated with gold particles
in order to determine the glycan location. It was found that P.
aeruginosa 1244 isolated pili did have gold particles along the
pilus (Figure 13).

P. aeruginosa 1244G7 did not have gold

particles on the pilus.

However, there was LPS contamination

located not on the pilus fiber but with debris surrounding the
pilus which caused gold particles to be seen in areas of LPS
clumping (Figure 14).

After additional purification cycles (as

described in the materials and methods section) of the 1244G7
pili, there was no debris found so no gold particles were found
(Figure 15).

This confirms the whole cell results that the

glycan is surface located.

It is found on the entire surface of

the pili and is not just concentrated at the tip of the fiber.
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2. Scanning Electron Microscopy
In order to confirm the TEM results, P. aeruginosa 1244 and
1244G7 cells were subjected to the procedure described above and
analyzed using SEM.

Controls are shown of P. aeruginosa 1244

and 1244G7 cells treated with the secondary antibody in the
absence of the monoclonal antibody in Figure 16 and 17,
respectively.

Gold particles were not seen on either of the

backscatter electron images suggesting that the primary
monoclonal antibody is needed for a reaction to be seen.

There

was no observable difference in appearance of the cells, pili,
or flagellum between the strains observed in the controls.
Next, the strains were treated with the monoclonal glycan
specific antibody, 11.14, and the secondary antibody conjugated
with gold particles.

In Figure 18, gold particles can be seen

on the P. aerguinosa 1244 pili shown in the secondary
backscatter electron images, therefore demonstrating that the
glycan is found over the entire surface of the pili and not just
at the tip of the fiber.

Gold labeling was also seen on the

cell surface of P. aeruginosa 1244. However, no gold particles
were seen on the P. aeruginosa 1244G7 pili shown in the
secondary backscatter electron image (Figure 19).

Gold labeling

was observed on the cell surface of P. aeruginosa 1244G7.

This

indicates that the results seen in Figure 18 were not due to LPS
contamination.

The SEM results confirmed the findings that the
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glycan is evenly distributed over the pilus fiber as found by
the TEM results.

Therefore, the glycan is only associated with

1244 glycosylated pili which is visualized using the secondary
backscatter electron images.

The cell surface of both strains

was strongly illuminated in the secondary backscatter electron
images by the reaction with the monoclonal antibody suggesting
that it is associated with the O-antigen of LPS found on the
cell surface.
The SEM results confirmed the finding of the TEM that the
glycan is surface-located and evenly distributed over the pilus
structure.

The glycan was only seen in the glycosylated 1244

strain of P. aeruginosa.
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Figure 5: P. aeruginosa 1244 whole cell, no primary or
secondary antibody. The negatively stained bacterium was
observed under 50K magnification on the Transmission Electron
Microscope.
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Figure 6: P. aeruginosa 1244G7 whole cell, no primary or
secondary antibody. The negatively stained bacterium was
observed under 50K magnification on the Transmission Electron
Microscope.
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Figure 7: P. aeruginosa 1244 whole cell with the 11.14 primary
antibody and secondary antibody conjugated with gold particles.
The negatively stained bacterium was observed under 50K
magnification on the TEM.
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Figure 8: P. aeruginosa 1244G7 whole cell with the 11.14
primary antibody and secondary antibody conjugated with gold
particles. The negatively stained bacterium was observed under
50K magnification on the TEM.
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Figure 9: P. aeruginosa 1244 whole cell, secondary antibody
conjugated with gold particles. The negatively stained
bacterium was observed under 50K magnification on the TEM.
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Figure 10: P. aeruginosa 1244G7 whole cell, secondary antibody
conjugated with gold particles. The negatively stained
bacterium was observed under 50K magnification on the TEM.

Pil

Flagellum

59

Figure 11: P. aeruginosa 1244 isolated pili, no primary antibody
and secondary antibody. The negatively stained bacterium was
observed under 25K magnification on the TEM.
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Figure 12: P. aeruginosa 1244G7 isolated pili, no primary
antibody and secondary antibody. The negatively stained
bacterium was observed under 25K magnification on the TEM.
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Figure 13: P. aeruginosa 1244 isolated pili, 11.14 primary
antibody and secondary antibody conjugated with gold particles.
The negatively stained bacterium was observed under 50K
magnification on the TEM.
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Figure 14: P. aeruginosa 1244G7 isolated pili, 11.14 primary
antibody and secondary antibody conjugated with gold particles.
The negatively stained bacterium was observed under 50K
magnification on the TEM.
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Figure 15: P. aeruginosa 1244G7 isolated pili, 11.14 primary
antibody and secondary antibody conjugated with gold particles.
To rid the sample of LPS contamination seen in figure 11, this
sample was further purified. The negatively stained bacterium
was observed under 50K magnification on the TEM.
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Figure 16: P. aeruginosa 1244, secondary antibody conjugated
with gold particles. The bacterium was viewed at 43K on the
scanning electron microscope. Panel A is the standard electron
digitized image and panel B is the field emission secondary
backscattered electron digitized image.
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Figure 17: P. aeruginosa 1244G7, secondary antibody conjugated
with gold particles. The bacterium was viewed at 43K on the
scanning electron microscope. Panel A is the standard electron
digitized image and panel B is the field emission secondary
backscattered electron digitized image.
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Figure 18: P. aeruginosa 1244, 11.14 primary antibody and
secondary antibody conjugated with gold particles. The
bacterium was viewed at 43K on the scanning electron microscope.
Panel A is the standard electron digitized image and panel B is
the field emission backscattered electron digitized image.
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Figure 19: P. aeruginosa 1244G7, 11.14 primary antibody and
secondary antibody conjugated with gold particles. The
bacterium was viewed at 43K on the scanning electron microscope.
Panel A is the standard electron digitized image and panel B is
the field emission backscattered electron digitized image.
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B. Immunogenicity of pilin glycan
1. Rabbit Studies
This set of experiments was designed to determine the
rabbit antibody response by immunization with pure LPS-free
pili.

Analysis of the antibodies produced would: 1) determine

the extent to which these pili stimulate the production of antiLPS antibodies, 2) produce a reagent that could be used for
opsonization assays, and 3) determine whether IgG or IgM is the
dominant anti-LPS antibody produced.
Each bleed was analyzed using the protocol described in
Materials and Methods. LPS was used as the antigen and anti-IgG
antibodies were used to detect the probe using an ELISA assay.
A graph in Figure 20 describes an overview of the progressive
increase in antibody production over the course of the
experiment.

The serum produced a high titer of IgG antibodies

at a dilution of 1 x 10-6 as shown in table 4.

The negative log

of serum dilutions were derived by using a constant endpoint of
0.100 (A410 for 30 minutes incubation at 30°C). This endpoint
provides a point where the three groups can be compared with one
another.
A Western blot using the DQ4 rabbit production bleed as the
primary antibody was completed with pure pilin or pure LPS as a
target (Figure 21).

There was a strong response seen in the
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lanes with pilin and in the lanes with LPS.

Therefore, the

Western blot illustrated two responses, a pili response and a
typical “ladder” response seen with LPS, which were recognized
by the rabbit antibodies.

This demonstrates that the rabbit

produces antibodies that recognize LPS when were injected with
pure LPS-free pili.
To determine whether there was a response against IgM
antibodies, an ELISA assay was completed with the terminating
bleed as the primary antibody and anti-IgM specific as the
secondary antibody.

A low titer of IgM antibodies were seen in

both rabbits (Figure 22).

There was a 4-log difference between

the IgM and IgG antibodies.

The IgM antibodies at the 0.05

endpoint were at a serum dilution of 1 x 10-2 while the IgG
antibodies had a serum dilution of 1 x 10-6.

Therefore, there is

an observable difference between the response of the level of
IgG and the IgM antibodies.
These assays showed that rabbits injected with pure LPSfree pili produced a strong titer of IgG antibodies directed
against LPS.

There was also a low titer of IgM antibodies

produced in the serum.

The rabbit serum were used in following

experiments to determine if there was opsonization.
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Figure 20: IgG Antibody Response against LPS from Rabbit DQ3 and
DQ4 summarized by a line graph. Secondary IgG antibody in the
ELISA assay was used to determine specific values of the
response. The amount of antibodies present continues to
increase with time. The highest titer is found from the
terminating bleed completed on 4-11-03.

1.40
1.20

Day 1 DQ3

Day 1 DQ4

Day 73 DQ3

Day 73 DQ4

Day 118 DQ3

Day 118 DQ4

1.00
0.80
0.60
0.40
0.20

Serum dilutions
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1x107

1x106

1x105

1x104

1x103

0.00

1x102

Amount of IgG Antibody
(Absorbance
at 405nm)
Absorbance
at 405nm

1.60

Table 4: Summary of IgG Antibody Response against LPS to pure
LPS-free pili in rabbits. Values were obtained from the ELISA
assay. All numbers were generated from a constant endpoint
which provides a point where the three groups can be compared
with one another.
Serum Used to
Days Past
DQ3 Rabbit
DQ4 Rabbit
Determine
Initial
Antibody
Antibody
Antibody Level
Immunization
Levels
Levels
(-log of serum
(-log of serum
dilution)
dilution)
Pre Bleed
1
0.00
0.00
12-10-02
Production
73
4.30
5.00
Bleed
2-21-03
Terminating
118
5.30
6.00
Bleed
4-11-03
Figure 21: Western Blot Analysis of DQ4 Rabbit Sera showing
anti-pilin and anti-LPS response. Lane 1 contained 5µl of
standard molecular marker. Lane 2, 3, and 4 had .25µg, .5µg,
and 1.0µg of pilin, respectively. Lane 5, 6, and 9 had nothing
added. Lane 7 and 8 have 30µl of LPS (7.5µg). The
nitrocellulose paper was incubated with the rabbit production
bleed sera diluted to 1:1000 in killer filler (Materials and
Methods).

41.3KB
27.4KB
20.8KB

15.5KB
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Figure 22: IgM Antibody Response against LPS using the rabbits’
termination bleed (118 days past initial immunization)
summarized by a line graph. Secondary IgM antibody was used to
determine specific values of the response. The IgM antibody is
strong in an initial response, however drops off quickly as
other immune responses begin to take action.

0 .3 0

(Absorbance at 405nm)

Amount of IgM antibodies

0 .3 5

D Q3
D Q4

0 .2 5
0 .2 0
0 .1 5
0 .1 0
0 .0 5

5 x 10-5

5 x 10-4

1 x 10-3

5 x 10-3

1 x 10-2

5 x 10-2

5 x 10^-5

1 x 10^-4

5 x 10^-4

1 x 10^-3

5 x 10^-3

1 x 10^-2

5 x 10^-2

1 x 10-4

0 .0 0

Se rum dilutions

2. Mouse Studies
In order to carry out a comprehensive protection studies
employing a pilus vaccine and using the mouse respiratory model,
it will be necessary to determine an optimal immunization
protocol.

A group of thirty 6-8 week old balb-c female mice

(20-25g) were obtained and immunized by the intranasal route
with 5µg, 10µg, or 20µg of pure LPS-free reaggregated pili or PBS
as a control (table 5).

A fecal, serum, and BAL (bronchial
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lavage) sample was collected from each mouse.

The fecal samples

would contain antibodies that would be present in the
gastrointestinal tract.

Because the antigen was processed via

the mucosal route, high antibody levels should be present in the
small intestine.

The serum samples were tested to determine the

titer of antibodies produced by the mouse that were present in
the blood.

The BAL samples were tested to reveal how many

antibodies were produced in the lungs, which was the site of
immunization.

The samples were used in an ELISA assay with LPS

as the antigen to determine the concentration of antibodies
present.
The results show that IgM are the type of antibodies being
produced in the serum of the mice throughout the duration of the
experiment (table 6-9).

The antibody levels from the mice that

were immunized with reaggregated pili were similar levels to the
antibody levels of the sham-immunized mice.

The BAL and fecal

samples produced no response in this experiment. IgA antibodies
were not present in any of the samples.

However, there was a

slight increase in IgG antibodies in the 20µg reaggregated piliinjected mice shown in table 8.

The sham-immunized mice also

produced a low response of IgG antibodies as shown in table 9.
Overall, there was an antibody response being produced in
this experiment, however the antibody levels produced by the
reaggregated-immunized mice and the sham-immunized mice were
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similar.

These levels from the mice did not correlate with the

rabbit immunogenicity results.

The rabbits produced a high

titer of IgG antibodies against pure LPS-free pili whereas the
mice did not produce a similar response against the same
antigen.

Table 5: Overview of Immunization of Mice Protocol.
started at the end of the five-day adjustment period.

Day
0

3

7

10

14

Day 0

Treatment
Immunization of Animals 1-8, 5µg of reaggregated pili
Immunization of Animals 9-16, 10µg of reaggregated pili
Immunization of Animals 17-24, 20µg of reaggregated pili
Sham immunization of Animals 25-30, PBS
Sacrificed Animals 1 & 2, 5µg of reaggregated pili
Sacrificed Animals 9 & 10, 10µg of reaggregated pili
Sacrificed Animals 17 & 18, 20µg of reaggregated pili
Sacrificed Animals 3 & 4, 5µg of reaggregated pili
Sacrificed Animals 11 & 12, 10µg of reaggregated pili
Sacrificed Animals 25 & 26, 20µg of reaggregated pili
Sacrificed Animals 25 & 26, PBS
Immunization of Animals 5-8, 5µg of reaggregated pili
Immunization of Animals 13-16, 10µg of reaggregated pili
Immunization of Animals 21-24, 20µg of reaggregated pili
Sham immunization Animals 27-30, PBS
Sacrificed Animals 5 & 6, 5µg of reaggregated pili
Sacrificed Animals 13 & 14, 10µg of reaggregated pili
Sacrificed Animals 21 & 22, 20µg of reaggregated pili
Sacrificed Animals 7 & 8, 5µg of reaggregated pili
Sacrificed Animals 15 & 16, 10µg of reaggregated pili
Sacrificed Animals 23 & 24, 20µg of reaggregated pili
Sacrificed Animals 27-30, PBS
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Table 6: Comparison of 5µg pure LPS-free reaggregated piliinjected mice at the endpoint on titration curves against LPS.
The values represent the –log of the antibody dilution. The
numbers in parenthesis stand for (the number of times the mice
were injected, the number of days the mice were terminated after
day 1).

FECAL
IgG

IgA

BAL

IgM

IgG

IgA

SERUM
IgM

IgG

IgA

IgM

Group 1 (1,3)

0

0

0

0

0

0

0

0

2.11

Group 2 (1,7)

0

0

0

0

0

0

0

0

1.42

Group 3 (2,10)

0

0

0

0

0

0

0

0

1.88

Group 4 (2,14)

0

0

0

0

0

0

0

0

1.19

Table 7: Comparison of 10µg pure LPS-free reaggregated piliinjected mice at the endpoint on titration curves against LPS.
The values represent the –log of the antibody dilution. The
numbers in parenthesis stand for (the number of times the mice
were injected, the number of days the mice were terminated after
day 1).

FECAL
IgG

IgA

Group 1 (1,3)

0

0

Group 2 (1,7)

0

Group 3 (2,10)
Group 4 (2,14)

BAL

IgM

IgG

IgA

0

0

0

0

0

0

0

0

0

0

0

0

SERUM
IgG

IgA

0

0

0

1.65

0

0

0

0

1.74

0

0

0

0

0

1.48

0

0

0

0

0

1.38
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IgM

IgM

Table 8: Comparison of 20µg pure
injected mice at the endpoint on
The values represent the –log of
numbers in parenthesis stand for
was injected, the number of days
day 1).

LPS-free reaggregated pilititration curves against LPS.
the antibody dilution. The
(the number of times the mouse
the mouse was terminated after

FECAL

BAL

IgG

IgA

IgM

IgG

IgA

Group 1 (1,3)

0.242

0.392

0

0

Group 2 (1,7)

0

0

0

Group 3 (2,10)

0

0

Group 4 (2,14)

0

0

SERUM
IgM

IgG

IgA

IgM

0

0

0.312

0

1.51

0

0

0

0.670

0

1.78

0

0

0

0

1.43

0

3.07

0

0

0

0

0

0

1.55

Table 9: Comparison of PBS-injected mice at the endpoint on
titration curves against LPS. The values represent the –log of
the antibody dilution. The numbers in parenthesis stand for
(the number of times the mouse was injected, the number of days
the mouse was terminated after day 1).

FECAL
IgG

IgA

Group 1 (1,7)

0

0

Group 2 (2,14)

0

0

BAL

IgM

IgG

IgA

0

0

0

0.134

0

0

SERUM
IgM

IgG

IgA

IgM

0

0

0

1.85

0

0.380

0

1.62

C. Protection Studies
1. Determination of Serum Sensitivity of
P. aeruginosa strains
Prior to the opsonization assays, P. aeruginosa strains
1244 and 1244.47 were tested for mouse serum sensitivity.

The

serum is used in the opsonization assay as a source of
antibodies, therefore if there was serum sensitivity then the
opsonization results would be invalid.

Strain 1244 was used in

this experiment because it expressed pili whereas 1244.47 did
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not produce any pili, therefore showing whether or not serum
resistance was due to the presence of pili.

Reaction 1

consisted of 70µl of bacterial cells at a concentration of 1x107
cells/ml and 30µl of saline whereas reaction 2 consisted of 70µl
of bacterial cells at a concentration of 1x107 and 30µl of
undiluted mouse serum from Sigma (St. Louis).

The two reactions

were incubated at 37°C, diluted, and plated on LB plates over
timed intervals.
morning.

The viable cells were counted the following

Neither strain was serum sensitive as shown in Figure

23, thus a factor(s) other than the presence of pili mediates
serum resistance.

Because these strains were not killed by the

mouse serum, opsonization assays can now be conducted using this
serum and these strains.
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Figure 23: Serum resistance assay results derived from 1244 and
1244.47. Reaction 1 contains 70µl of bacterial cells at a
concentration of 1x107 and 30µl of saline. Reaction 2 contains
70µl of bacterial cells at a concentration of 1x107 and 30µl of
undiluted mouse serum. The two reactions were incubated at 37°C,
diluted, and plated on LB plates over timed intervals.
Measurements are made in the number of viable colonies.
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2. Opsonization Assay
Opsonization is the process whereby antibodies attach to an
invading bacterium making it more vulnerable to phagocytosis.
Polymorphonuclear leukocytes (PMNs) are a type of white blood
cell, abundant in mammalian blood, and engulf bacteria via
phagocytosis.

The goal of the opsonization assays was to

determine whether or not the antibodies in the serum from
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rabbits that were immunized with pure LPS-free pili could
enhance the killing of the bacteria by the PMNs.

In addition,

these assays would reveal if phagocytosis was due to a pilusspecific or LPS-specific response by the rabbit antibodies.
Various combinations of PMNs from human volunteers, rabbit
serum, saline, human complement, and bacterial cells were
incubated at 37°C, diluted, and plated on LB plates over timed
intervals.

As a control to ensure that the assay was

functioning properly, strains E. coli HB101, which lacks an Oantigen, and P. aeruginosa 1244wbpL, which has no O-antigen but
does possess non-glycosylated pili, were used.

E. coli HB101

and P. aeruginosa 1244wbpL should be susceptible to PMN killing
(Boyer H.W., 1969), even in the absence of serum due to the
absence of an O-antigen.

Furthermore, opsonization should occur

in tests using P. aeruginosa 1244 wbpL because of the presence
of anti-pilus antibodies in the serum.

The results showed that

killing of the bacteria was observed in the assays using strains
E. coli HB101 and P. aeruginosa 1244wbpL which conveys that the
assay is functioning properly (Figure 24).
Since the control strains showed that the assay was working
properly, P. aeruginosa 1244 and 1244.47 were tested for
opsonization using the rabbit antibodies and PMNs as previously
described.

Strains 1244, which possesses glycosylated pili, and

1244.47, which does not produce pili, were used to show whether
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or not opsonization was pili-mediated.

However, if both strains

decreased in the number of viable cells, then the results would
suggest an LPS-mediated response because these strains share the
same O-antigen.

Results showed no decrease of viable cells of

either strain (Figure 25). This assay was repeated utilizing
various types of complement such as baby rabbit and human, all
with the same negative results.
Overall, the results suggest that P. aeruginosa 1244 and
1244.47 were resistant to phagocytosis by PMNs since killing was
not observed. Therefore, the rabbit serum was unable to elicit
opsonization in these strains due to the high resistance to
phagocytosis exhibited by P. aeruginosa 1244 and 1244.47.
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Figure 24: Opsonization assay results derived from E. coli HB101
and P. aeruginosa 1244wbpL. Control run consisted of 100µl of
bacterial cells and 300µl of saline. The test run consisted of
100µl bacterial cells, 100µl white blood cells (PMNs), 100µl
human complement, and 100µl rabbit serum. Both the control and
the test run were incubated at 37°C, diluted, and plated on LB
plates over timed intervals. Measurements were then made in the
number of colonies.
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Figure 25: Opsonization assay results derived from strains 1244
and 1244.47. Control run consisted of 100µl of bacterial cells
and 300µl of saline. The test run consisted of 100µl bacterial
cells, 100µl white blood cells (PMNs), 100µl human complement,
and 100µl rabbit serum. Both the control and the test run were
incubated at 37°C, diluted, and plated on LB plates over timed
intervals. Measurements are made in the number of colonies.
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IV. Discussion
A. Electron Microscopy
The pili of P. aeruginosa are made up of a single type of
pilin subunit which has the physical and chemical
characteristics associated with those of the type IV pili (Strom
and Lory, 1993).

One of these characteristics is the N-

methylation of the amino-terminal residue, phenylalanine.

In

addition to this modification, the carboxy-terminal residue, a
serine, of P. aeruginosa 1244 pilin is glycosylated (Comer et
al., 2002).

This glycan is a trisaccharide that is identical

with the O-antigen repeating unit of the lipopolysaccharide
produced by this organism (Castric et al., 2001).

Pilin

glycosylation by this organism requires the presence of pilO, a
gene that is a component of the operon containing pilA, the
pilin structural gene (Castric, 1995).
Another characteristic of the Type IV pili is the presence
of a disulfide loop (DSL) adjacent to the carboxy-terminus.

The

DSL is important in pilus-mediated adhesin (Lee et al., 1994)
and is a dominant B-cell epitope (Comer et al., 2002).

Lee et

al. (1994) have shown that the DSL is surface-located only at
the pilus tip.

The proximity of the pilin glycan to the DSL

brings in to question its location on the pilus fiber.

The

present study provides evidence by using monoclonal glycan-
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specific antibodies that the glycan is located at the pilus
surface.

Further, the results show that this structure is

distributed evenly over the pilus.
These findings suggest that the hydrophilic nature of the
glycan can be expected to have a significant effect on the
physical and chemical properties of the pilus.

The pilus is

normally hydrophobic (Castric, unpublished), however, the glycan
on the surface of this structure makes it less hydrophobic and
more hydrophilic.

The glycan is negatively charged due to the

ionic character of Pseudaminic acid found at the glycan
terminus.

Hydrogen bonding of the sugar residues increases

hydrophilicity.
The presence of the pilin glycan likely influences pilus
function.

Since LPS and the glycan have identical structure,

this may play a direct role in adhesion for the bacteria because
LPS is a known adhesin.

Therefore, the glycan may be an adhesin

as well where is could possibly aid or modify binding to host
epithelial cells in various parts of the body.
Studies done by Smedley (2001) have shown that the pilus
glycan has a direct effect on twitching motility.

He found that

the P. aeruginosa 1244 mutant, which was unable to glycosylate
pilin, was able to synthesize functional pili.
twitching was ~26% less than the wild type.

Its average

This could be due

to the absence of the glycan on the pilus surface.
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The negative

charge and hydrophilicity produced by the glycan may alter the
interactions between the pili and other structures external to
the cell.

To see if this is the case, experiments measuring the

interaction of purified glycosylated and non-glycosylated pili
to cells will need to be carried out.
The glycan may also aid in epitope masking of the pilusbinding site by sterically blocking antibodies from binding.

By

blocking the binding site, this would hinder the ability for the
antibodies from the immune system to bind to the bacterial
cells.

It would be advantageous for the bacterium to defend

itself in this way since the immune system upon initial
infection responds by producing antibodies for neutralization of
the bacterial cells.

This would increase the success of the

bacteria to be able to initiate an infection.
The results found in this study show that a vaccine could
be effective against pili. Since the glycan is located over the
entire surface of the pilus, it is highly concentrated with many
binding sites available.

This allows cross-linking to occur

which will result in inhibition or decreased twitching (Castric
et al., 2001) by the pili.

Since the twitching motility has

been linked to the bacterium’s pathogenicity, then inhibiting
twitching will cause it to be avirulent.

This could be an

important point in making an effective vaccine.

Also, the pili

have identical structure to the O-antigen repeating unit of LPS
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and LPS cannot be injected into humans due to endotoxin A,
therefore the glycosylated pili would be a good vaccine
candidate against all strains of Pseudomonas. It would not
matter whether they had pili or not since they all have LPS to
respond against.
Overall, the results from the TEM illustrate that P.
aeruginosa 1244 pili are glycosylated in which the glycan is
located over the entire surface of the fiber shown by the gold
particles. Whereas 1244G7 is not glycosylated shown by the lack
of gold particles on the pili.

Gold particles were seen on the

cell surface of 1244 and 1244G7 which suggests that the antiglycan antibodies recognize the LPS present.
The SEM results also suggested that the glycan location was
found on the entire surface of the pili and not restricted to
the tip.

These results showed that the TEM method was working

and the results seen were not an artifact from the negative
staining or fixation.
Future direction in this area could include observations of
various strains to examine pili characteristics such as length
or abundance in strains express glycosylated versus nonglycosylated pili.

Transmission electron micrographs could be

taken and the pili could be counted and compared statistically.
Other P. aeruginosa strains producing glycosylated pili such as
577B (Castric and Deal, 1994) could be examined to extend the
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results that the glycan is surface located over the entire
fiber.
B. Immunogenicity of pilin glycan
1. Rabbit Studies
This set of experiments was designed to determine the
antibody titer produced by rabbits that were immunized with pure
LPS-free pili.

Analysis of the antibodies produced would: 1)

demonstrate whether or not the pili produce anti-LPS antibodies,
2) produce a reagent that could be used for opsonization assays,
and 3) determine whether IgG or IgM is the dominant antibody
produced.
The rabbits were immunized with pure LPS-free pili, however
the antibodies produced were able to recognize LPS and pili.
Presumably, this was due to an immune response to the pilin
glycan that is identical in structure to the O-antigen repeating
unit.

The results also show a high titer of IgG antibodies

which indicates a T-dependent response.

A T-dependent response

is desired since memory B cells would be produced against the
antigen.

If O-antigen was used to immunize the rabbits, one

would not expect to see high IgG antibody level because sugars
normally don’t produce a T-dependent response.

Because the O-

antigen repeating unit was covalently bound to pilin protein, it
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induced a T-dependent response which would not have been seen by
vaccinating with O-antigen alone.
The results could be beneficial to creating an effective
pili-based vaccine since antibodies produced from immunization
with glycosylated pili recognize LPS as well as pili.

It would

be able to provide protection against all strains with O7
antigen and pili like that of 1244.
The high titer of antibodies produced could be due to the
rabbits being immunized by many different routes such as
intradermally, intramuscularly, and subcutaneously.

Utilizing

various routes of immunization allowed for the antigen to spread
over the entire body increasing the possibility for a higher
amount of antibodies to be produced by the rabbit.

Another

explanation for the high levels of antibodies is the number of
times the rabbits were immunized along with the length of the
experiment.
Future studies could include a long-term protection study
where mice would be immunized with pure LPS-free glycosylated
pili. Following a long period of time, the pilus/LPS antibody
levels would be determined by use of ELISA assays.

If high

antibody levels are still present, this would suggest that
memory response has taken place which is indicative of Tdependence.

The preliminary results of a long-term protection

study using mice are described in the next section.
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2. Mouse Studies
Marshall (masters thesis, 2001) was able to conclude that
the pilus glycan was a major immunogenic region on the pili of
P. aerguinosa 1244.

Preliminary evidence has been presented by

Horzempa (unpublished) that the P. aeruginosa 1244 pilin glycan
was a protective epitope.

This work was carried out using the

intranasal mouse challenge model.

My studies were carried out

to determine optimal conditions for immunization using this
system.

These experiments were done for preliminary values in

order to allow comprehensive protection studies in the future.
The intranasal route of immunization was chosen for its ability
to induce an IgA antibody response in respiratory secretions.
This IgA response is significant in protecting against
pneumonias caused by P. aeruginosa.

The intranasal route was

also chosen because it can be administered in a painless manner.
A fecal, serum, and BAL sample was collected for each mouse
to determine the number and type of antibodies associated with
each sample.

The fecal samples would contain antibodies that

would be present in the gastrointestinal tract.

Because the

antigen was processed via the mucosal route, high antibody
levels should be present in the small intestine.

The serum

samples were tested to determine the titer of antibodies
produced by the mouse that were present in the blood.
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The BAL

samples were tested to reveal how many antibodies were produced
in the lungs, which was the site of immunization.
Each sample was tested for IgG, IgA, and IgM antibodies by
an ELISA assay.

These antibodies were chosen because the

dominant antibody between IgG and IgM would suggest whether a Tdependent or a T-independent response was being produced.
antibodies are the primary mucosal antibodies.

IgA

The IgA titer

would aid in determining the potential protection level acquired
for this route of immunization.
Overall, the antibody levels from the mice that were
immunized with reaggregated pili were similar levels to the
antibody levels of the sham-immunized mice.

The results show

IgM antibodies in the serum, although it was thought that the
levels would be much higher due to the antibody levels produced
in the rabbit study.

IgM antibodies usually appear as one of

the first host immune responses and then taper off as IgG
antibodies are produced. This does correlate with the appearance
of IgG antibodies in the serum samples of the 20µg reaggregated
pili category as the IgM antibodies begin to disappear.
No significant antibody levels could be detected in the BAL
sample.

Previous studies (unpublished work by Held, Castric,

and Cross) show a high titer of anti-pilin IgA antibodies found
in the BAL sample when the mice were immunized with native pili
intranasally.

In the current experiment, mice were immunized
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with pure LPS-free reaggregated pili, and levels of anti-LPS
antibodies were detected.

Whereas, Held et al. immunized mice

with native pili that were possibly contaminated with low levels
of LPS.

ELISA assays conducted by Held et al. utilized pili as

the antigen therefore detecting anti-pilin antibodies.

My study

detected anti-LPS antibodies as LPS was used as the antigen in
the ELISA assays.

Future studies could be conducted using the

mouse serum tested with pili as the antigen in an ELISA assay.
This may reveal similar anti-pilin antibody levels to those
discovered by Held et al.

LPS contamination could also have

contributed to the high levels of antibodies (Pier, 1982) found
by Held et al., since the antibodies that would react with Oantigen would also react with pilin.
Antibody titer levels in this study also differ from those
found in the study by Comer et al. (2001).

Comer et al.

immunized the mice by injecting them subcutaneously at the nap
of the neck whereas the intranasal method was used for this
study.

They found antibody levels significantly higher than the

sham mice.

Therefore, the intranasal route of immunization

induces a lesser antibody response than a subcutaneous
immunization.

Marshall (masters thesis, 2001) also noticed that

reaggregated pili induced lower levels of anti-LPS antibodies
than native pili when introduced subcutaneously.
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As previously mentioned, the low titer of antibodies could
be due to the route of immunization used.

The mice were

immunized intranasally which affects the mucosal system.

This

kept the antigen contained in one area unlike the rabbits that
were immunized in various places over the entire body.

Another

explanation of the low levels of antibodies is the number of
times the mice were immunized along with the length of the
experiment.

At the most, the mice were only immunized twice

with comparison to the rabbits that received six immunizations.
This experiment only lasted two weeks while the rabbit
immunizations continued for four months.

In addition, mice and

rabbits do not always exhibit similar immune response when
subjected to the same antigen (Priebe, G.P., 2002).
The absence of antibodies that react with LPS may be due to
the treatment used to produce the reaggregated pili.

The glycan

may be buried inside the pilus when the fibers are reassembled,
therefore leaving a decreased number of glycan epitopes
available at the surface.

This hypothesis could be tested by

taking transmission electron micrographs of the reaggregated
pili with the glycan-specific monoclonal antibody and secondary
antibody conjugated with gold particles.
Since optimal conditions are not established for this
system, further work in this area will include completing this
protocol using native and nonglycosylated pili.
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The mice will

be subject to the same immunization method to determine if there
is a variation between glycosylated and nonglycosylated pili.
This experiment could also be repeated using different
immunization methods to determine which vaccine route provides
the best response.
C. Protection Studies
Pseudomonas aeruginosa was tested for background levels of
serum sensitivity and PMN (polymorphonuclear luekocyte) killing.
Prior to opsonization studies, strains were tested for serum
sensitivity.

If the strains were serum sensitive, then they

could not be tested for opsonization.
The mouse serum was used to test P. aeruginosa 1244 and
1244.47 for any serum sensitivity.

This was done to determine

if the system could detect killing by opsonization.

The results

showed no killing of the bacteria in these assays which
demonstrates that P. aeruginosa 1244 and 1244.47 are serum
resistant.
Since the strains tested were found to be serum resistant,
phagocytosis assays were completed to determine if there was any
opsonization when glycan-specific antibodies were present.

To

ensure that the phagocytosis assay was working properly, it was
tested with E.coli HB101 and P. aeruginosa 1244wbpL.

E.coli

HB101 is a highly transformable strain which produces no O
antigen (Sambrook et al., 1989).
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P. aeruginosa 1244wbpL

produces non-glycosylated pili and also does not possess an O
antigen (DiGiandomenico et al., 2002).

The presence of an O-

antigen layer is characteristic of cells that are resistant to
phagocytosis.

As described in the results section, there was a

decrease in viable cells indicating that the assay was working
properly.
P. aeruginosa 1244 and 1244.47 were tested for opsonization
by the extent of PMN killing.

The results showed that there was

no decrease in viable cell count indicating that there was no
killing of the bacteria by the PMNs.

However, this was not the

expected result since the function of the PMNs is to fight
against the bacteria when it enters the body.

O-antigen on P.

aeruginosa 1244 and 1244.47 could be causing the PMNs to be
inactivated or unable to perform their function of killing the
bacteria (Engels et al., 1985) since E. coli HB101 and P.
aeruginosa 1244wbpL did have a decrease in viable cells.
Another possibility of this assay not working could be due to
weakened PMNs from the human volunteer whose immune system could
be stressed.
Results from the opsonization assay show that P. aeruginosa
1244 is extremely resistant to phagocytosis which means that it
should not be used in these types of assays.

Determination of

protection by opsonization tests may not be practical.

Even

though 30% rabbit serum concentration is high, this experiment
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could be repeated using 100% serum concentration by resuspending
P. aeruginosa 1244 and 1244.47 in the serum.

With a higher

serum concentration, the bacteria may not remain resistant
therefore a decrease in viable cells would be seen.
Future experiments could be conducted using mouse serum
rather than rabbit serum, or complement from other animals than
those tested.

However, this assay utilized various types of

complement such as baby rabbit and human, all with the same
negative results, it is unlikely that using mouse complement
would change the outcome.
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